Compare ZKIN & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | NORD |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Professional Services |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 95.5M |
| IPO Year | 2017 | 2005 |
| Metric | ZKIN | NORD |
|---|---|---|
| Price | $1.52 | $3.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 23.9K |
| Earning Date | 08-21-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,346.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $3.02 |
| 52 Week High | $2.99 | $5.28 |
| Indicator | ZKIN | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 24.00 |
| Support Level | $1.30 | $3.02 |
| Resistance Level | $1.57 | N/A |
| Average True Range (ATR) | 0.11 | 0.66 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 55.41 | 22.12 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.